文獻(xiàn)： 1、" Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. " Pharmacotherapy 2007;27:290–8. Page RL, Schwiesow J, Hilts A. 2、Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013;39:310–24. Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. 3、Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. 4、J Med Chem, 51: 4632～4640. Org. Process Res. Dev. 2019, 23, 9, 2057-2068 Pharmazie 73(9):494-497 · September 2018 5、中國醫(yī)藥工業(yè)雜志 2012， 43（8）， 644-646 6、精細(xì)化工中間體2013，43（2），46-48 7、精細(xì)化工中間體2011，41（4），46-48 8、中國現(xiàn)代應(yīng)用藥學(xué)2011，28（1），58-59 9、Chemical biology&Drug Design 2014, 83(3), 306-316 10、Letters in organic chemistry 2012, 9(4), 276-279 11、Medicines Evidence Commentary : Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders Source: National Institute for Health and Care Excellence - NICE - 21 January 2014 - Publisher: National Institute for Health and Care Excellence (NICE) 12、double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children 13、J. Med. Chem. 2018, 61, 5304?5322. 14、Chem. Biol. Drug Des. 2014, 83, 306?316. 15、J. Pharm. Biomed. Anal. 2009, 50, 144?150. 16、Int. J. Pharm. Sci. 2016, 8, 97?102. 17、J. Pharm. Biomed. Anal. 2010, 52, 493?507. 18、Org. Process Res. Dev. 2013, 17, 1036?1041. 19、Beilstein J. Org. Chem. 2011, 7, 442? 495. 20、Bioorg. Med. Chem. Lett. 2014, 24, 1108?1110. 21、New Activated PEG Derivatives for Affinity Partitioning 22、Population incidence and mortality of sepsis in an urban African setting 2013-2016 23、Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in   [更多]

急需冷敷凝膠、冷敷貼及傷口敷料的一類醫(yī)療器械全套備案申請(qǐng)資料   [更多]

求助西地那非原料藥信息   [更多]

提供藥廠及藥品轉(zhuǎn)讓項(xiàng)目/合作項(xiàng)目，需要具體的轉(zhuǎn)讓信，企業(yè)名稱，聯(lián)系方式，信息需真實(shí)可靠。   [更多]

1、Clinical Features and Molecular Genetics of HSD387 Deficiency and AKRlD1 Deficiency A case report of inborn errors of bile acid synthesis 2、3B-hydroxy-△5-C27 steroid dehydrogenase deficiency: a case report 3、Hallas G. Chem. and Ind. 1972,691 4、Chemical and biological characterization of iron-protein succinylate (ITF 282)' 5、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

EP10.0藥典： 1、Piperacillin Sodium EP10.0 2、替加環(huán)素Tigecycline EP10.0 3、阿托品atropine EP10.0 4、硫酸阿托品 EP10.0 5、2.6.31 EP10.0 6、EP10.0: Salmeterol Xinafoate 7、EP10.0: Preparations for inhalation 8、EP10.0: Pressurised pharmaceutical preparations" 9、EP10:ceftazidime 10、Formoterol Fumarate EP10.0 11、乳酸依沙吖啶Ethacridine lactate monohydrate EP10.0 12、Aspartame的EP10.0標(biāo)準(zhǔn) 13、EP10.0 3.1.9 14、perindopril tert-butylamine的EP10.1標(biāo)準(zhǔn) 15、CALCIUM LEVOFOLINATE HYDRATE EP10.0 16、Deslanoside EP10 17、Inhalation powders EP10 18、Fluconazole EP10 19、Nifedipine EP10 20、Calcium Dobesilate Monohydrate 羥苯磺酸鈣原料藥EP10.0的標(biāo)準(zhǔn) 21、EP10.0 Ipratropium bromide 22、Voriconazole EP10.0 23、Magnesium Stearate硬脂酸鎂 EP10.0 24、Colloidal Anhydrous Silica膠態(tài)無水二氧化硅 EP10.0 25、Purified water 純化水 EP10.0 26、Povidone (K-90) 聚維酮 (K-90) EP10.0 27、Hydroxypropyl cellulose (EF)羥丙纖維素 (EF) EP10.0 28、HPMC E-15羥丙甲纖維素E-15 EP10.0 29、Purified Talc 滑石粉 EP10.0 30、Pregelatinised Starch 預(yù)膠化淀粉 EP10.0 31、Lactose Monohydrate一水乳糖 EP10.0 32、lsopropyl Alcohol異丙醇 EP10.0 33、Titanium dioxide二氧化鈦 EP10.0 34、Polyethylene glycol 400 聚乙二醇400 EP10.0 35、氨丁三醇 TROMETAMOL EP10.0 36、依地酸鈣鈉 SODIUM CALCIUM EDETATE EP10.0 37、碘帕醇 IOPAMIDOL EP10.0 38、甘露醇 MANNITOL 查EP10.0 39、Macrogol 4000 EP10.0 40、鹽酸二甲雙胍Metformin hydrochloride，EP10.0 41、Polyoxyl castor oil EP10.0 42、Ascorbic Acid-EP10.0 43、EP10.0中的（5.1.8） 44、EP10.0中的（5.1.4） 45、Carboxymethylcellulose sodium的最新歐洲藥典，然后這個(gè)monograph（專著）里面有一個(gè)取代度的具體方法。 EP10.0 46、Tranexamic Acid EP10.0 47、歐洲藥典10.0版Starches hydrocyethyl 48、Dextrose和Glucose monohydrate EP10標(biāo)準(zhǔn) 49、Oxcarbazepine EP10標(biāo)準(zhǔn) 50、Human albumin solution EP10標(biāo)準(zhǔn) 51、Cefoperazone Sodium EP10.0 52、Sulbactam Sodium EP10.0 53、Azithromycin、 EP10標(biāo)準(zhǔn) 54、Aripiprazole EP10.0 55、 Candesartan cilexetil EP10.0 56、Clopidogrel besilate EP10.0 57、Clopidogrel hydrogen sulfate EP10.0 58、Clopidogrel hydrochloride EP10.0 59、Duloxetine hydrochloride EP10.0 60、Galantamine hydrobromide EP10.0 61、Irbesartan EP10.0   [更多]

1、targeting inhaled steroids 文獻(xiàn) 2、Minerva Dietol Gastroenterol. 1989 Jul-Sep;35(3):175-89. [A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. [Article in Italian] Del Tacca M, Danesi R, Blandizzi C, Bernardini MC. 3、See 1 citation found by title matching your search: J Pharmacol. 1985;16 Suppl 2:145-69. [MI cholinergic receptors of gastric secretion: current status]. [Article in French]、 4、Carrigan PJ, Papp K, Schulz G, Venable T. Bioavailability of valproate from divalproex sodium tablets. Abbott Laboratories, North Chicago, IL (unpublished data). 5、MITOXANTRONE - MECHANISM OF ACTION, ANTITUMOR-ACTIVITY, PHARMACOKINETICS, EFFICACY IN THE TREATMENT OF SOLID TUMORS AND LYMPHOMAS, AND TOXICITY，文獻(xiàn) 6、American Journal of Kidney Diseases Volume 70, Issue 6, December 2017, Pages 737-751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)   [更多]

1、Nimesulide - a non-steroidal anti-inflammatory drug, a preferential cyclooxygenase-2 inhibitor 【出處】Vutreshni bolesti. 2000;32(1):33-6. 2、Bioequivalence study between two slow release batches ofindapamide SR 1.5 mg with different dissolution pro- files after repeated oral administration over 7 days in 12 healthy volunteers: a randomised double blind cross over study. Fulmer Hall, UK: Servier, 1993. Report No.: NP 910 3、Schiavi P, Jochemsen R, Hiley M, et al. Pharmacokinetics ofslow and immediate release formulations of indapamide after single oral administration under fasting conditions and after food, in healthy volunteers. Eur J Drug Metab Pharmacokinet 1996; Spe- cial Issue: 42 4、找一篇97年的政策法規(guī)文件，標(biāo)題：國家醫(yī)藥管理局國藥字（97）253號(hào)文件 5、Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder. Jpn J Clin Psychopharmacol 2009;12:1613-1634   [更多]

具體要求： 1.懸賞2013年1月1日之后NMPA批準(zhǔn)的藥品信息 2.必須提供完整信息，以附件形式提交 3.核實(shí)后如果正確，每個(gè)獎(jiǎng)勵(lì)30元 4.投稿時(shí)請(qǐng)隱藏提交 5.請(qǐng)勿在百度上直接搜索 6.需是藥智網(wǎng)未收集的數(shù)據(jù)   [更多]

EP10.0: 1. 昔萘酸沙美特羅Salmeterol Xinafoate 2. 對(duì)氨基水楊酸鈉Sodium Aminosalicylate Dihydrate 3. 亞胺培南Imipenem monohydrate 4. 西司他丁鈉Cilastatin sodium 5. 制霉菌素Nystatin 6. ω-3 脂肪酸甘油三酯Omega-3-Acid Triglycerides 7. 噻托溴銨一水合物Tiotropium Bromide Monohydrate 8. 硫酸沙丁胺醇Sulbutamol Sulphate 文獻(xiàn)： 1、Preventative approaches for neurophathy in diabetes with Alpha-lipoic Acid 2奧硝哩 在人體 內(nèi)的代謝與排泄研究 杜江 波 ” , 尤 天庚 ’ , 陳笑艷 ’ , 鐘 大放 ” 1. 中國科學(xué)院上海藥物研究所 , 上海 2 0 1 2 03 2 . 上海東方醫(yī)院 , 上海 2 0 01 2 0   [更多]